Treatment of Early Allergic and Late Inflammatory Symptoms of Allergic Rhinitis with Petasites Hybridus Leaf Extract (Ze 339): Results of a Noninterventional Observational Study in Switzerland

Abstract

The primary objective of this noninterventional, observational study was to assess the effectiveness of the Petasites hybridus leaf extract (Ze 339) on early allergic and late inflammatory symptoms of allergic rhinitis in Swiss outpatients. This study was conducted by general practitioners and allergologists. Data from 226 patients were collected during three documented visits. The intermediate visit was ideally made 2–4 weeks after the baseline visit, followed by the final visit approximately 2–4 months later. The mean study duration was 63 days, with 75% of patients being treated for at least 4 weeks. Of the patients, 58.5% started with Ze 339 monotherapy, and 41.5% received other antiallergic and/or sympathomimetic drugs. In both groups, the allergic total symptom score and the inflammatory total symptom scores were significantly (p < 0.001) reduced, and the scores for quality of life were improved. Both physicians and patients were very satisfied with the treatment and the concept of therapy, not only for short-term (seasonal) therapy but also for long-term therapy. The tolerability was good: only three mild gastrointestinal adverse events occurred. In summary, the effectiveness of P. hybridus leaf extract Ze 339 for the treatment of early allergic and late inflammatory symptoms of allergic rhinitis could be confirmed.

The Petasites hybridus CO2 Extract (Ze 339) Blocks SARS-CoV-2 Replication In Vitro

“…Further, Ze 339 is available for self-medication. Clinical and post-marketing surveillance studies did not reveal any safety concerns [59][60][61][62][63]. The range and incidence of adverse effects in the respective studies were very low, and described adverse events had all previously been known and are included in the summary of product characteristics [64].…”

The Petasites hybridus CO2-extract (Ze 339) blocks SARS-CoV-2 replication in vitro

“…Further, Ze 339 is available for self-medication. Clinical and postmarketing surveillance studies did not reveal any safety concerns [59][60][61][62][63]. The range and incidence of adverse effects in the respective studies were very low; described adverse events had all previously been known and are included in the summary of product characteristics [64].…”

Karadeniz Bölgesinde yetişen bazı yenilebilir yabani otlar ve biyoaktif özellikleri

“…Halk hekimliğinde solunum yolu rahatsızlıkları, sindirim sistemi hastalıkları ve baş ağrısının tedavisinde kullanıldığı beliritilmektedir (26). Bitkiden elde edilen ekstraktların ve bileşiklerin migren, alerjik rinnit, meme kanseri ve SARS-CoV-2 üzerinde etkili olduğu bilinmektedir (27)(28)(29)(30). Ayıca bitki antimikrobiyal ve antioksidan etki göstermektedir (31).…”